Insmed reported $-163.56M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
BioMarin Pharmaceutical USD 105.53M 152.1M Mar/2026
Cytokinetics USD -206.03M 23M Mar/2026
DBV Technologies USD -47.6M 2.77M Mar/2026
Gilead Sciences USD -10.5B 12.52B Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -163.56M 164.92M Mar/2026
Novartis USD 3.16B 747M Mar/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026